Teva Announces Successful Upsizing and Pricing of $2.3 Billion Senior Notes

Summary

Teva Pharmaceutical Industries Limited successfully upsized and priced approximately $2.3 billion (equivalent) of its senior notes. The proceeds will be used to fund tender offers for existing debt, pay fees and expenses, and repay outstanding debt. The senior notes include €1 billion of 4.125% Euro-denominated notes due 2031, $500 million of 6.000% USD-denominated notes due 2032, and $700 million of 5.750% USD-denominated notes due 2030.